AKT2 SiRNA Delivery with Amphiphilic-based Polymeric Micelles Show Efficacy Against Cancer Stem Cells

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2018 Apr 19

PMID 29667444

Citations 14

Authors

Diana Rafael

Petra Gener

Fernanda Andrade

Joaquin Seras-Franzoso

Sara Montero

Yolanda Fernandez

Manuel Hidalgo

Diego Arango

Joan Sayos

Helena F Florindo

Ibane Abasolo

Simo Schwartz Jr

Mafalda Videira

Affiliations

Soon will be listed here.

Abstract

Development of RNA interference-based therapies with appropriate therapeutic window remains a challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. A new amphihilic-based gene delivery system that combines Pluronic F127 micelles with polyplexes spontaneously formed by electrostatic interaction between anionic siRNA and cationic polyethylenimine (PEI) 10K, was designed (PM). Resultant PM gather the requirements for an efficient and safe transport of siRNA in terms of its physicochemical characteristics, internalization capacity, toxicity profile and silencing efficacy. PM were loaded with a siRNA against AKT2, an important oncogene involved in breast cancer tumorigenesis, with a special role in CSC malignancy. Efficacy of siAKT2-PM was validated in CSC isolated from two breast cancer cell lines: MCF-7 and Triple Negative MDA-MB-231 corresponding to an aggressive subtype of breast cancer. In both cases, we observed significant reduction on cell invasion capacity and strong inhibition of mammosphere formation after treatment. These results prompt AKT2 inhibition as a powerful therapeutic target against CSC and pave the way to the appearance of more effective nanomedicine-based gene therapies aimed to prevent CSC-related tumor recurrence.

Citing Articles

Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.

Sai B, Dinakar Y, Kumar H, Jain R, Kesharwani S, Kesharwani S Ther Deliv. 2024; 15(11):871-891.

PMID: 39320858 PMC: 11498026. DOI: 10.1080/20415990.2024.2400044.

A Novel Tendon Injury Model, Induced by Collagenase Administration Combined with a Thermo-Responsive Hydrogel in Rats, Reproduces the Pathogenesis of Human Degenerative Tendinopathy.

Vidal L, Lopez-Garzon M, Venegas V, Vila I, Dominguez D, Rodas G Int J Mol Sci. 2024; 25(3).

PMID: 38339145 PMC: 10855568. DOI: 10.3390/ijms25031868.

Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells.

Gil M, Khouri L, Raurell I, Rafael D, Andrade F, Abasolo I Pharmaceutics. 2023; 15(10).

PMID: 37896223 PMC: 11340786. DOI: 10.3390/pharmaceutics15102463.

Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance.

Eid R, Alaa Edeen M, Shedid E, Kamal A, Warda M, Mamdouh F Int J Mol Sci. 2023; 24(2).

PMID: 36675306 PMC: 9861138. DOI: 10.3390/ijms24021786.

Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype.

Grassilli S, Brugnoli F, Cairo S, Bianchi N, Judde J, Bertagnolo V J Pers Med. 2022; 12(6).

PMID: 35743776 PMC: 9224635. DOI: 10.3390/jpm12060993.

References

Batrakova E, Li S, Alakhov V, Miller D, Kabanov A . Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther. 2003; 304(2):845-54. DOI: 10.1124/jpet.102.043307. View

Gener P, Gouveia L, Sabat G, Rafael D, Fort N, Arranja A . Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine. 2015; 11(8):1883-92. DOI: 10.1016/j.nano.2015.07.009. View

Rafael D, Doktorovova S, Florindo H, Gener P, Abasolo I, Schwartz Jr S . EMT blockage strategies: Targeting Akt dependent mechanisms for breast cancer metastatic behaviour modulation. Curr Gene Ther. 2015; 15(3):300-12. DOI: 10.2174/1566523215666150126123642. View

Alakhova D, Zhao Y, Li S, Kabanov A . Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One. 2013; 8(8):e72238. PMC: 3747131. DOI: 10.1371/journal.pone.0072238. View

Yu Y, Ramena G, Elble R . The role of cancer stem cells in relapse of solid tumors. Front Biosci (Elite Ed). 2011; 4(4):1528-41. DOI: 10.2741/e478. View

Bai J, Wang J, Mei K, Al-Jamal W, Al-Jamal K . Real-time monitoring of magnetic drug targeting using fibered confocal fluorescence microscopy. J Control Release. 2016; 244(Pt B):240-246. PMC: 5176088. DOI: 10.1016/j.jconrel.2016.07.026. View

Zhang S, Zhao B, Jiang H, Wang B, Ma B . Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release. 2007; 123(1):1-10. DOI: 10.1016/j.jconrel.2007.07.016. View

Shim M, Kwon Y . Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010; 277(23):4814-27. DOI: 10.1111/j.1742-4658.2010.07904.x. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

10.

Minko T, Batrakova E, Li S, Li Y, Pakunlu R, Alakhov V . Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release. 2005; 105(3):269-78. PMC: 2711210. DOI: 10.1016/j.jconrel.2005.03.019. View

11.

Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H . Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol. 2014; 9(9):1324-31. PMC: 4154841. DOI: 10.1097/JTO.0000000000000250. View

12.

Jung H, Park K, Han D . Preparation of TGF-β1-conjugated biodegradable pluronic F127 hydrogel and its application with adipose-derived stem cells. J Control Release. 2010; 147(1):84-91. DOI: 10.1016/j.jconrel.2010.06.020. View

13.

Martinez-Garcia R, Juan D, Rausell A, Munoz M, Banos N, Menendez C . Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med. 2014; 6(4):27. PMC: 4062047. DOI: 10.1186/gm544. View

14.

Cheng G, Zhang W, Sun M, Wang Q, Coppola D, Mansour M . Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 2008; 283(21):14665-73. PMC: 2386910. DOI: 10.1074/jbc.M707429200. View

15.

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

16.

Alakhova D, Rapoport N, Batrakova E, timoshin A, Li S, Nicholls D . Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J Control Release. 2009; 142(1):89-100. PMC: 3113470. DOI: 10.1016/j.jconrel.2009.09.026. View

17.

Diniz I, Chen C, Xu X, Ansari S, Zadeh H, Marques M . Pluronic F-127 hydrogel as a promising scaffold for encapsulation of dental-derived mesenchymal stem cells. J Mater Sci Mater Med. 2015; 26(3):153. PMC: 4477746. DOI: 10.1007/s10856-015-5493-4. View

18.

Andrade F, das Neves J, Gener P, Schwartz Jr S, Ferreira D, Oliva M . Biological assessment of self-assembled polymeric micelles for pulmonary administration of insulin. Nanomedicine. 2015; 11(7):1621-31. DOI: 10.1016/j.nano.2015.05.006. View

19.

Deng Y, Wang C, Choy K, Du Q, Chen J, Wang Q . Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014; 538(2):217-27. DOI: 10.1016/j.gene.2013.12.019. View

20.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View